Clinical Trials
11
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (11 trials with phase data)• Click on a phase to view related trials
Study of Posoleucel (ALVR105,Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant
- Conditions
- Epstein-Barr Virus InfectionsHuman Herpes Virus-6 InfectionJC Virus InfectionCytomegalovirus InfectionsAdenovirus InfectionBK Virus Infection
- First Posted Date
- 2022-03-31
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- AlloVir
- Target Recruit Count
- 451
- Registration Number
- NCT05305040
- Locations
- 🇺🇸
University of Alabama at Birmingham Children's of Alabama, Birmingham, Alabama, United States
🇺🇸Honor Health Research Institute, Scottsdale, Arizona, United States
🇺🇸City of Hope, Duarte, California, United States
Posoleucel (ALVR105) for the Treatment of Adenovirus Infection in Pediatric and Adult Participants Receiving Standard of Care Following Allogeneic Hematopoietic Cell Transplantation
- First Posted Date
- 2022-01-05
- Last Posted Date
- 2024-05-08
- Lead Sponsor
- AlloVir
- Target Recruit Count
- 57
- Registration Number
- NCT05179057
- Locations
- 🇺🇸
MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸Phoenix Children's Hospital, Phoenix, Arizona, United States
🇺🇸City of Hope, Duarte, California, United States
Study of ALVR106 in Patients With Respiratory Viral Infections After Hematopoietic Cell and Solid Organ Transplant
- Conditions
- Respiratory Tract Viral InfectionsHuman Metapneumovirus (hMPV) InfectionRespiratory Syncytial Viral (RSV) InfectionInfluenza InfectionParainfluenza (PIV) Infection
- First Posted Date
- 2021-06-22
- Last Posted Date
- 2024-06-06
- Lead Sponsor
- AlloVir
- Target Recruit Count
- 17
- Registration Number
- NCT04933968
- Locations
- 🇺🇸
Scottsdale Healthcare Hospitals DBA HonorHealth, Scottsdale, Arizona, United States
🇺🇸City of Hope, Duarte, California, United States
🇺🇸University of Florida - Division of Hematology & Oncology, Gainesville, Florida, United States
Posoleucel (ALVR105, Formerly Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant
- Conditions
- Cytomegalovirus InfectionsHuman Herpes Virus-6 InfectionAdenovirus InfectionEpstein-Barr Virus InfectionsBK Virus InfectionJC Virus Infection
- First Posted Date
- 2021-01-05
- Last Posted Date
- 2024-05-09
- Lead Sponsor
- AlloVir
- Target Recruit Count
- 26
- Registration Number
- NCT04693637
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸City of Hope National Medical Center, Duarte, California, United States
🇺🇸University of California, San Francisco Medical Center, San Francisco, California, United States
Study of Posoleucel (Formerly Known as ALVR105; Viralym-M) in Kidney Transplant Patients With BK Viremia
- Conditions
- BK Virus NephropathyBK Virus Infection
- First Posted Date
- 2020-10-28
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- AlloVir
- Target Recruit Count
- 61
- Registration Number
- NCT04605484
- Locations
- 🇺🇸
Keck Medical Center of USC, Los Angeles, California, United States
🇺🇸Stanford University, Palo Alto, California, United States
🇺🇸University of California Davis Medical Center, Sacramento, California, United States
- Prev
- 1
- 2
- 3
- Next
News
CMV Treatment Pipeline Expands with 20+ Therapies from Leading Pharmaceutical Companies
DelveInsight's 2025 assessment reveals 15+ companies are developing over 20 cytomegalovirus (CMV) infection treatment therapies across various clinical development phases.
Kalaris and AlloVir Complete Merger to Advance Novel Anti-VEGF Therapy for Retinal Diseases
• Kalaris Therapeutics and AlloVir have finalized their merger, with the combined entity operating under the Kalaris name and trading on Nasdaq as KLRS, led by CEO Andrew Oxtoby. • The merged company has secured approximately $100 million in cash, providing financial runway into Q4 2026 to support the continued development of TH103, a novel anti-VEGF therapy for retinal diseases. • TH103, engineered by Dr. Napoleone Ferrara, aims to address limitations of current neovascular age-related macular degeneration treatments with initial Phase 1 data expected in the second half of 2025.
Novel mRNA Vaccine Shows Promise in Phase 3 Trials for Cytomegalovirus Prevention
• A groundbreaking mRNA vaccine (mRNA-1647) demonstrates superior efficacy against cytomegalovirus infection in phase 3 clinical trials, offering new hope for preventing CMV transmission. • The global CMV infections market is projected to experience significant growth across seven major markets, with a diagnosed population of 111,000 cases reported in 2022. • Leading pharmaceutical companies including ModernaTX, Merck Sharp & Dohme, GlaxoSmithKline, and AlloVir are developing innovative therapies to address unmet needs in CMV treatment.
Allovir and Kalaris Therapeutics Merge to Focus on Retinal Disease Therapies
• Allovir Inc. will merge with Kalaris Therapeutics Inc., shifting focus to therapies for neovascular and exudative retinal diseases. • The combined company, Kalaris Therapeutics Inc. (KLRS), will advance TH-103, an anti-VEGF treatment, currently in a Phase I study for neovascular age-related macular degeneration (nAMD). • Phase I study data readout for TH-103 is anticipated in the third quarter of 2025, marking a key milestone for the merged entity's pipeline. • The strategic merger aims to address conditions like nAMD, diabetic macular edema, and retinal vein occlusion, leveraging Kalaris' existing assets.